VCS Test vs Mycotoxin Test: What Each Measures and Which to Take First
The VCS test and the urine mycotoxin panel are frequently presented as competing options, as though one were a cheaper substitute for the other. They measure different things. The VCS test measures an effect on you. The mycotoxin panel measures a substance leaving you. A person can plausibly be positive on one and negative on the other without either result being wrong.
That distinction governs everything below, including the sequencing question most people actually arrive with, which is not which test is better but which one to spend money on first.
Note: Mold and mould are the same thing, spelled differently on either side of the Atlantic. This article uses the American spelling throughout.
What the VCS test measures
Visual Contrast Sensitivity testing measures your ability to distinguish faint differences between light and dark, presented as a series of striped grating patches at five spatial frequencies. The protocol derives from the Functional Acuity Contrast Test developed by Arthur Ginsburg and adapted for biotoxin screening through Dr Ritchie Shoemaker's clinical work.
The relevance to mold rests on a physiological chain. Biotoxin exposure in susceptible people triggers an inflammatory response involving complement fragment C4a, which constricts small blood vessels and reduces perfusion. The capillaries supplying the optic nerve are among the most vulnerable to that reduction, and the neurons handling mid-range spatial frequencies, around 6 and 12 cycles per degree, degrade first. The deficit can appear within 24 to 36 hours of exposure and reverses as inflammation settles.
What the test therefore reports is whether your nervous system is currently showing the functional signature of biotoxin exposure. Reported sensitivity sits near 92 percent for CIRS-pattern illness with a false positive rate below 1 percent, and combining the visual result with a validated symptom questionnaire raises combined screening accuracy to approximately 98.5 percent.
Our page on the VCS test sets out the accuracy figures, eligibility rules, and screen requirements in full. For the comparison here, its practical characteristics matter as much as its statistics. The screen takes roughly fifteen minutes, runs in a browser after screen calibration, requires no sample collection or laboratory, and can be repeated as often as you like, which makes it usable for tracking response to treatment rather than only for a one-off answer.
Start your testWhat the mycotoxin urine test measures
A urine mycotoxin panel looks for the toxic compounds certain molds produce, and their metabolites, in a sample your kidneys have filtered. It is a biomarker of exposure and excretion, meaning it reports what your body has encountered and is currently clearing.
Two analytical platforms account for most testing. Mass spectrometry, specifically LC-MS/MS, separates compounds and identifies each by mass and fragmentation pattern, which offers high specificity. Mosaic Diagnostics, formerly Great Plains Laboratory, reports eleven mycotoxins on this platform. Competitive ELISA, an antibody-based method used by RealTime Laboratories, reports sixteen including nine macrocyclic trichothecenes, with greater sensitivity for certain compounds but a higher potential for cross-reactivity.
The panels target the mycotoxins with the clearest human relevance: ochratoxin A, produced by Aspergillus and Penicillium species and the most commonly detected of the group; trichothecenes, associated with Stachybotrys and water-damaged buildings; gliotoxin, produced by Aspergillus and Candida; aflatoxins from Aspergillus flavus; and zearalenone. Results arrive as detected or not detected against the laboratory's lower limit of quantification, with values expressed in parts per billion or, more usefully, adjusted for creatinine to correct for how dilute the sample was.
Cost runs to a few hundred dollars depending on laboratory and panel size, turnaround is typically one to two weeks, and insurance rarely covers it. Our full guide to mycotoxin urine testing covers collection protocol, the provocation question, and reading a report in detail.
The two tests side by side
| VCS test | Urine mycotoxin panel | |
|---|---|---|
| What is measured | A neurological effect currently present in you | Compounds currently leaving you |
| Timing of the signal | Appears within 24 to 36 hours, improves inside two weeks of effective treatment | Reflects excretion at the moment of collection |
| Cost and access | Free here, needs only a calibrated screen | A few hundred dollars, sample collection and shipping |
| Repeatability | Weekly at no cost, suits treatment tracking | Paid each time, so usually run once or twice |
| What it cannot establish | Which biotoxin, which source, which species | Whether the compounds are making you unwell, or whether they came from the building or the diet |
| Main confounders | Acuity below 20/50, cataracts, glaucoma, macular degeneration, a trained visual baseline | Hydration, kidney function, diet, detoxification capacity |
What is measured. VCS assesses a neurological effect currently present in you. The mycotoxin panel quantifies compounds currently leaving you.
Timing of the signal. Visual contrast deficits appear within 24 to 36 hours of exposure and improve as inflammation resolves, with meaningful change often visible inside two weeks of effective treatment. Urinary mycotoxins reflect what is being excreted at the moment of collection, which depends on recent exposure, fat storage, and how well your detoxification pathways are functioning.
Cost and access. The VCS screen is free here and requires only a calibrated screen. The urine panel is a paid laboratory service ordered directly or through a practitioner, requiring sample collection, shipping, and preparation including a fasting window and avoidance of binders for around seventy-two hours beforehand.
Repeatability. VCS can be repeated weekly at no cost, which suits treatment tracking. Repeating a mycotoxin panel means paying again, so most people run it once or twice.
What each cannot establish. VCS cannot identify which biotoxin is involved, cannot distinguish mold from Lyme or other biotoxin sources, and cannot name a species. The mycotoxin panel cannot tell you whether the compounds it found are making you unwell, nor whether they arrived from your building or your diet, since ochratoxin A in particular is common in coffee, wine, dried fruit, and cereal grains.
Susceptibility to confounders. VCS results are affected by visual acuity below roughly 20/50, cataracts, glaucoma, macular degeneration, and by an unusually high baseline in people whose professions train their vision. Mycotoxin results are affected by hydration, kidney function, diet, and detoxification capacity.
Why "which is more accurate" is the wrong comparison
Accuracy figures for the two tests describe different questions, so placing them beside each other implies a competition that does not exist.
The 92 percent sensitivity attached to VCS describes how often the test correctly flags people who have CIRS-pattern illness. That is a statement about detecting an illness pattern. Mycotoxin panels using validated LC-MS/MS methods report analytical recoveries in the region of 93 to 114 percent, which is a statement about correctly measuring a compound present in a sample. Both numbers are legitimate measures of what they were designed to assess, and neither substitutes for the other.
The more useful frame is what each test is qualified to conclude. VCS supports the inference that something is producing a biotoxin-pattern neurological effect. The mycotoxin panel supports the inference that specific compounds are present and being excreted. Confidence rises when those two independent lines of evidence agree, which is the actual argument for running both rather than choosing between them.
What each combination of results means
Since the two tests report on different layers of the same problem, the four possible combinations each carry a distinct interpretation.
The strongest configuration for a mold-related explanation, particularly alongside a documented damp or water-damaged environment and a consistent symptom pattern. Exposure is demonstrated and a functional effect is present. This combination generally justifies environmental investigation and a conversation with a mold-literate clinician.
Common, and frequently misread as contradictory. Several explanations fit this pattern. Detoxification may be impaired, so the compounds are retained rather than excreted, which is discussed in the next section. The biotoxin involved may not be a mycotoxin at all, since Lyme co-infections, cyanobacteria, and other sources produce the same visual signature. Exposure may have ended long enough ago that excretion has fallen below detection while inflammation continues. Or binders taken before collection may have diverted compounds into stool.
Exposure has occurred without producing a measurable neurological effect. This is the expected result for the majority of people, who clear biotoxins normally, and for dietary exposure to ochratoxin A. Reviewing diet before the building is sensible here.
Mold-related illness becomes considerably less likely, though not excluded. The VCS false negative rate sits near 8 percent and concentrates in people with naturally high baseline contrast sensitivity, including artists, photographers, pilots, athletes, and habitual gamers. Where symptoms persist and clearly track a building, the honest reading is that the cause has not yet been identified rather than that mold has been ruled out.
Why the sickest people often test negative on urine
This point deserves separating out, because it inverts the intuitive reading of a negative mycotoxin result and it is the single most consequential thing to understand before ordering one.
Urine testing depends entirely on excretion. The panel can only detect what your kidneys are actively clearing, which means a result reflects your capacity to eliminate mycotoxins as much as it reflects your burden of them. In people whose detoxification pathways are functioning well, exposure produces detectable excretion. In people whose pathways are impaired, and impaired clearance is precisely the mechanism proposed for why roughly a quarter of the population develops CIRS after exposure that leaves others unaffected, the compounds are retained rather than passed.
Clinicians working in this area report the resulting paradox directly: the most unwell people frequently return the lowest urinary mycotoxin values, because the same failure of clearance that made them ill also prevents the test from finding evidence of it. A negative panel in a symptomatic person with a documented damp environment therefore carries much less exclusionary weight than a negative result normally would.
This is also the strongest practical argument for pairing the two tests. VCS does not depend on excretion at all. It measures the consequence of retained biotoxins rather than the passage of cleared ones, which makes it informative exactly where urine testing is weakest.
Which test to take first
Sequencing follows from cost and from what each result unlocks.
Beginning with VCS is reasonable for almost everyone, since it is free, immediate, repeatable, and independent of excretion. A positive result establishes that a biotoxin-pattern effect is present and justifies the expense of laboratory work. A negative result, in someone whose symptoms do not clearly track a building, argues for investigating other explanations before spending several hundred dollars.
Proceeding to a mycotoxin panel makes sense once VCS and symptoms both point toward biotoxin involvement, when you want to know which compounds are involved, or when documentation is needed for a clinician, a landlord, or an insurer. Specific compounds also carry different implications, since detected trichothecenes point toward a water-damaged building while ochratoxin A alone may reflect diet.
Running both simultaneously suits people whose exposure history is already well documented, who have a clinician waiting on results, or whose circumstances make a second round of testing impractical.
Where the situation is ambiguous, the pattern in time and place remains the cheapest evidence available. Symptoms that ease after several days away from a building and return within a day of coming back point at the environment more reliably than either test does in isolation, and the symptoms associated with mold toxicity are worth reviewing against your own before spending anything.
The screening runs in your browser and takes about fifteen minutes from calibration to result.
Start the test nowWhere blood markers and home testing fit
Neither of these two tests examines the building, and neither characterises the immune response, so a complete picture usually draws on two further categories.
Inflammatory blood markers, including C4a, TGF-beta1, MMP-9, MSH, and VIP, describe how the immune system is responding rather than what it was exposed to. They are ordered through a clinician, cost more, and are read as a pattern rather than individually. They sit naturally after a positive VCS result when a practitioner is involved.
Environmental testing, principally ERMI and HERTSMI-2 dust analysis, assesses the property rather than the person. Since remediating the source is what ends exposure, a positive body test with no identified environmental source leaves the problem unsolved. Where you already hold results from any of these, our test interpreter reads mycotoxin panels, ERMI and HERTSMI-2 scores, and CIRS blood markers in plain language.
The conclusions worth trusting come from agreement across categories: a building that tests positive, a body excreting the corresponding compounds, an immune system showing the inflammatory pattern, and a neurological effect that improves once exposure ends.
Frequently asked questions
Is the VCS test or the mycotoxin test more accurate?
Their accuracy figures answer different questions. VCS reports roughly 92 percent sensitivity for detecting CIRS-pattern illness, which measures how often it identifies affected people. Validated mycotoxin methods report analytical recoveries around 93 to 114 percent, which measures how precisely they quantify a compound in a sample. Neither figure can be substituted for the other.
Can I be positive on VCS and negative on the mycotoxin panel?
Yes, and it is common. Impaired detoxification can prevent excretion of the compounds causing the effect, the biotoxin may come from a non-fungal source such as a Lyme co-infection, exposure may have ended while inflammation continues, or binders taken before collection may have diverted compounds into stool.
Which test should I do first if I can only afford one?
The VCS screen, since it costs nothing, returns a result in about fifteen minutes, can be repeated, and does not depend on your ability to excrete. Its result also indicates whether paid laboratory testing is justified.
Does a negative mycotoxin test rule out mold illness?
No, and it carries less exclusionary weight than people assume. The panel measures excretion, so poor detoxifiers, who are disproportionately the people who become ill, can return low values while carrying a significant burden. A negative panel alongside a positive VCS result and a damp environment warrants further investigation rather than reassurance.
Can the VCS test tell me which mold I was exposed to?
No. It detects a functional pattern consistent with biotoxin exposure without identifying the source, and Lyme co-infections, cyanobacteria, and other biotoxins produce a similar signature. Identifying specific compounds requires the mycotoxin panel, and identifying species in a property requires environmental testing.
How much does each test cost?
The VCS screen is free here and needs only a calibrated screen. Urine mycotoxin panels run to a few hundred dollars depending on the laboratory and the number of compounds tested, and are generally not covered by insurance.
Can I use either test to track whether treatment is working?
VCS suits this well, since it is free, repeatable, and responds within weeks, with clinicians commonly retesting weekly in early recovery and stretching the interval as progress holds. Repeat mycotoxin panels are used for the same purpose but cost money each time and can rise temporarily during treatment as stored compounds mobilise.
Do I still need home testing if my body tests are positive?
Yes, if the source has not been identified. Body testing establishes exposure and effect without locating the origin, and exposure continues until the environmental source is found and corrected, which is why ERMI or HERTSMI-2 dust testing usually follows a positive result.